Huntington’s Disease Treatment Market Trends and Updates 2020 – Global trends, Industry Top Leaders, Comprehensive Analysis, Devices Type, Regional Segments, Innovation and Forecast to 2026

SEATTLE, March 24, 2021, (PHARMIWEB) — Huntington’s disease, also known as Huntington’s chorea, is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. It deteriorates a person’s physical and mental abilities during their prime working years, i.e. age between 30 and 35 years. Generally, Huntington’s disease is related to movement disorders, cognitive disorders or psychiatric disorders. Over the time, an individual suffering from Huntington’s becomes vulnerable to pneumonia, heart failure or some other complications that can lead to death. Huntington’s disease is diagnosed by neurological examination, neuropsychological testing, psychiatric evaluation, genetic test, and brain imaging and functioning. The symptomatic treatment is primarily used for the treatment of Huntington’s disease, which involves use of drugs such as tetrabenazine, antidepressants, antipsychotic or mood-stabilizing. Moreover, there are other supplementary treatments are used such as psychotherapy, speech therapy, physical therapy, occupational therapy or lifestyle and home remedies.

*The Sample consists of Table of Content, Research framework of the actual report & research methodology adopted for it.
To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/1479

Growing prevalence of disease and increasing R&D activities by institutes and universities are expected to drive growth of the global Huntington’s disease treatment market during the forecast period. According to Huntington’s disease Society of America, there are approximately 30,000 symptomatic people in the U.S. and over 200,000 at-risk of inheriting the disease. Furthermore, various organization such as CHID Foundation, Huntington’s Disease Society of America, Hereditary Disease Foundation, and International Huntington Association are working proactively to create awareness among patients and their family, which is expected to fuel growth of the global Huntington’s disease treatment market in the near future.

However, social stigma associated with Huntington’s disease, strict government regulations related to drug approvals, and limited approved drug are expected to restrain growth of the global Huntington’s disease treatment market in the near future.

Exclusive offer!!! Purchase the report at a discounted rate!!!

Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount

Quick Buy – Huntington’s Disease Treatment Market Research Report: https://bit.ly/2OTSpqr

Global Huntington’s disease Treatment Market Dynamics:

By Drug Type:

• Tetrabenazine
• Deutetrabenazine
• Other Drug Type

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Huntington’s disease Treatment Market Drivers:

Although there is no definite cure for Huntington’s disease, clinicians are slowing down degeneration of the neurons as the only effective solution. Global Huntington’s disease treatment market is dominated by off-labeled drugs, which creates opportunity for key players, to develop new drugs. In 2017, Teva Pharmaceuticals Ltd. received the U.S. Food and Drug Administration (FDA) approval for its Austedo, a generic of deutetrabenazine indicated for Huntington’s disease after Xenazine. Furthermore, Laquinimod and Pridopidine are in Phase 2 clinical trials for the treatment of Huntington’s disease. Moreover, tetrabenazine is been studied by Lundbeck, in 2017, for its ability to reduce impulsiveness, depression, and suicidal tendencies for patients suffering from Huntington’s disease and it is in Phase 4 clinical trials. This increase in R&D activities and strong company pipelines are factors expected to drive growth of the global Huntington’s disease treatment market.

Various institutes and universities are involved in research programs to develop novel therapies such as cell and gene-based therapies for the treatment of the disease, which in turn, is expected to drive the market growth in the near future. Reversing cell loss due to degeneration is most likely a target for Huntington’s disease treatment. Neurogenesis and regeneration of neurons are the novel therapies used for restoration or manipulation of neuron cell by using stem cell therapy. Another such approach is lowering Huntingtin protein production, which is leading cause of Huntington’s disease. For instance, IONIS HTT by Ionis Pharmaceuticals, Inc., collaborated with Roche, targets reduced production of Huntingtin protein, a genetic cause for the disease, via antisense drug technology. IONIS HTT was in phase 1/2a as in 2015. Moreover, key players are also focusing on use of neurotropic factors or cell transplantation. Therefore, development of various new therapies for treatment of Huntington’s disease is expected to aid in growth of the market over the forecast period.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/huntingtons-disease-treatment-market-1479

Competitive Landscape

Major players operating in the global Huntington’s disease treatment market are Valeant Pharmaceuticals International Inc., Alnylam Pharmaceuticals Inc., Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer limited, Palobiofarma S.L, Omeros and Ipsen.

Table of Content

Global Huntington’s Disease Treatment Market Research Report
Section 1: Global Huntington’s Disease Treatment Industry Overview
Section 2: Global Economic Impact on Huntington’s Disease Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Huntington’s Disease Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Huntington’s Disease Treatment Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837